Viking Therapeutics is progressing through a critical phase in the competitive obesity therapeutics market, which is projected to exceed $100 billion in global revenue by 2030. The company's lead candidate, VK2735, a dual GIP/GLP-1 receptor agonist, is currently advancing through phase 3 clinical trials in both injectable and oral formulations, with the company expected to announce significant trial data and launch additional studies throughout 2026.
The dual agonist approach represents a differentiated mechanism within the weight loss drug sector, which has experienced substantial growth following the commercial success of established GLP-1 therapies. VK2735's dual formulation strategy—targeting both injectable and oral delivery—positions the company to address diverse patient preferences and treatment modalities should the candidate receive regulatory approval.
The outcomes of Viking's 2026 clinical milestones will be instrumental in determining the company's competitive standing within the sector. While the pipeline presents meaningful growth potential, shareholders should carefully evaluate the clinical development timeline and regulatory pathway risks inherent in late-stage drug development.